ArticleRheumatology (Oxford, England)2026
Risk of chronic kidney disease in newly diagnosed SLE with preserved renal function: a national study.
Article in Rheumatology (Oxford, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesSLE is strongly associated with LN, a major cause of chronic kidney disease (CKD). However, long-term renal and cardiovascular outcomes in patients with SLE who have preserved kidney function and do not develop LN remain poorly characterized. We sought to investigate the development of CKD among newly diagnosed patients with SLE who had preserved kidney function and no evidence of concomitant LN at baseline, compared with matched control individuals.
methodsA national database study of newly diagnosed patients with SLE between 2015 and 2023. Patients with estimated glomerular filtration rate (eGFR) > 60 ml/min/1.73 m2 at diagnosis were matched to non-SLE controls by age, sex and ethnicity. Patients with LN were excluded. The primary outcome was incident CKD, defined as eGFR ≤ 60 ml/min/1.73 m2 after diagnosis. Secondary outcomes included end-stage kidney disease (ESKD), major adverse cardiovascular events (MACE) and all-cause mortality.
resultsWe identified 1145 patients with SLE and 91 681 matched controls, with a median follow-up of 5.77 years and similar baseline eGFR (103 vs 104 ml/min/1.73 m2). SLE was associated with a higher risk of CKD (5.2% vs 2.7%; HR 1.96, 95% CI 1.50-2.54), ESKD (HR 3.13, 95% CI 1.38-7.08), MACE (HR 1.63, 95% CI 1.31-2.04) and all-cause mortality (HR 4.52, 95% CI 3.71-5.50). Mean eGFR trajectories were similar between the groups. Diabetes (HR 1.51, 95% CI 1.39-1.64) and hypertension (HR 2.72, 95% CI 2.42-3.07) were the strongest risk factors for CKD and ESKD.
conclusionPatients with SLE and preserved kidney function at diagnosis, without LN, are at increased risk of adverse renal outcomes, cardiovascular events and mortality, highlighting the importance of long-term monitoring and optimization of modifiable CKD risk factors.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.